Alcami

Manufacturing

CorMedix hit with another CRL in effort to get nod for DefenCath

The FDA has slapped troubled biotech CorMedix with its second complete response letter because of manufacturing issues with DefenCath.
Kevin Dunleavy Aug 9, 2022 10:00am

Sterling plots ADC specialist buyout in early 2021

Dec 2, 2020 10:07am

CDMO Sterling acquires former Alcami ingredients facility

Oct 1, 2020 9:39am

Madison Dearborn Partners snatches up CDMO Alcami

Jun 4, 2018 2:06pm